The year 2020 started on a promising note with key pharmaceutical companies focusing on oncology as their major trial area. Though the number of oncology trials registered in 2019 and Q1 2020 are high,
infectious diseases have taken a second spot replacing major therapeutic areas such as central nervous system (CNS) and cardiology. The impact of COIVD-19 has forced many pharmaceutical companies to divert their attention from existing portfolios and work towards infectious diseases trials.
Dr. Siddhartha Dutta